Bisneto, J. V., Burke, J. M., Tun, A., Liu, S., Sharman, J., Biondo, J., Jani, P., Wu, M., Mun, Y., Chopra, V. S., Farighi, R., Muñoz, J., Yunus, F., Flinn, I., Budde, E. (2025). Fixed-duration subcutaneous mosunetuzumab demonstrates sustained clinically meaningful outcomes in patients with previously untreated, low-tumor burden follicular lymphoma. Blood. https://doi.org/10.1182/blood-2025-1807